Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity
Objective Monthly scanning with triple-dose gadopentetate dimeglumine has been shown to be associated with progressive increases in bone T1 hyperintensity, hypophosphatemia, and leukopenia. This study was performed to retrospectively investigate the potential associations among these phenomena. Meth...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-02-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/03000605221076977 |
| _version_ | 1818905400376819712 |
|---|---|
| author | Daniel Chen Ivan Wolansky Jaime Imitola Carl Malchoff Rong Wu Suhayl Dhib-Jalbut Ketan Bulsara Leo Wolansky |
| author_facet | Daniel Chen Ivan Wolansky Jaime Imitola Carl Malchoff Rong Wu Suhayl Dhib-Jalbut Ketan Bulsara Leo Wolansky |
| author_sort | Daniel Chen |
| collection | DOAJ |
| description | Objective Monthly scanning with triple-dose gadopentetate dimeglumine has been shown to be associated with progressive increases in bone T1 hyperintensity, hypophosphatemia, and leukopenia. This study was performed to retrospectively investigate the potential associations among these phenomena. Methods This retrospective analysis involved patients who had received monthly triple-dose gadopentetate dimeglumine for up to 2 years as part of treatment for multiple sclerosis. Monthly magnetic resonance imaging scans of the brain (n = 67) were segmented to evaluate the signal intensity in the cranial marrow. Potential associations among the marrow T1 hyperintensity, serum phosphate concentration, and white blood cell count were examined. Results Patients in the no leukopenia group showed a statistically significant mean monthly increase in the bone marrow signal-to-noise ratio of 0.0430/month. Patients in the leukopenia group showed a mean monthly increase in the bone marrow signal-to-noise ratio of 0.0398/month, but this was not statistically significant. Patients in the hypophosphatemia group were significantly less likely to develop leukopenia than patients who had never developed hypophosphatemia. Conclusions Although monthly administration of triple-dose gadopentetate dimeglumine over 13 months has been associated with progressive increases in leukopenia, hypophosphatemia, and T1 signal intensity of bone, this study showed an inverse relationship between leukopenia and hypophosphatemia. |
| first_indexed | 2024-12-19T21:22:44Z |
| format | Article |
| id | doaj.art-1fad735b09f44940a5a2d1c17829c673 |
| institution | Directory Open Access Journal |
| issn | 1473-2300 |
| language | English |
| last_indexed | 2024-12-19T21:22:44Z |
| publishDate | 2022-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of International Medical Research |
| spelling | doaj.art-1fad735b09f44940a5a2d1c17829c6732022-12-21T20:05:11ZengSAGE PublishingJournal of International Medical Research1473-23002022-02-015010.1177/03000605221076977Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensityDaniel ChenIvan WolanskyJaime ImitolaCarl MalchoffRong WuSuhayl Dhib-JalbutKetan BulsaraLeo WolanskyObjective Monthly scanning with triple-dose gadopentetate dimeglumine has been shown to be associated with progressive increases in bone T1 hyperintensity, hypophosphatemia, and leukopenia. This study was performed to retrospectively investigate the potential associations among these phenomena. Methods This retrospective analysis involved patients who had received monthly triple-dose gadopentetate dimeglumine for up to 2 years as part of treatment for multiple sclerosis. Monthly magnetic resonance imaging scans of the brain (n = 67) were segmented to evaluate the signal intensity in the cranial marrow. Potential associations among the marrow T1 hyperintensity, serum phosphate concentration, and white blood cell count were examined. Results Patients in the no leukopenia group showed a statistically significant mean monthly increase in the bone marrow signal-to-noise ratio of 0.0430/month. Patients in the leukopenia group showed a mean monthly increase in the bone marrow signal-to-noise ratio of 0.0398/month, but this was not statistically significant. Patients in the hypophosphatemia group were significantly less likely to develop leukopenia than patients who had never developed hypophosphatemia. Conclusions Although monthly administration of triple-dose gadopentetate dimeglumine over 13 months has been associated with progressive increases in leukopenia, hypophosphatemia, and T1 signal intensity of bone, this study showed an inverse relationship between leukopenia and hypophosphatemia.https://doi.org/10.1177/03000605221076977 |
| spellingShingle | Daniel Chen Ivan Wolansky Jaime Imitola Carl Malchoff Rong Wu Suhayl Dhib-Jalbut Ketan Bulsara Leo Wolansky Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity Journal of International Medical Research |
| title | Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity |
| title_full | Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity |
| title_fullStr | Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity |
| title_full_unstemmed | Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity |
| title_short | Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity |
| title_sort | monthly triple dose gadolinium administration potential associations with leukopenia hypophosphatemia and bone marrow t1 hyperintensity |
| url | https://doi.org/10.1177/03000605221076977 |
| work_keys_str_mv | AT danielchen monthlytripledosegadoliniumadministrationpotentialassociationswithleukopeniahypophosphatemiaandbonemarrowt1hyperintensity AT ivanwolansky monthlytripledosegadoliniumadministrationpotentialassociationswithleukopeniahypophosphatemiaandbonemarrowt1hyperintensity AT jaimeimitola monthlytripledosegadoliniumadministrationpotentialassociationswithleukopeniahypophosphatemiaandbonemarrowt1hyperintensity AT carlmalchoff monthlytripledosegadoliniumadministrationpotentialassociationswithleukopeniahypophosphatemiaandbonemarrowt1hyperintensity AT rongwu monthlytripledosegadoliniumadministrationpotentialassociationswithleukopeniahypophosphatemiaandbonemarrowt1hyperintensity AT suhayldhibjalbut monthlytripledosegadoliniumadministrationpotentialassociationswithleukopeniahypophosphatemiaandbonemarrowt1hyperintensity AT ketanbulsara monthlytripledosegadoliniumadministrationpotentialassociationswithleukopeniahypophosphatemiaandbonemarrowt1hyperintensity AT leowolansky monthlytripledosegadoliniumadministrationpotentialassociationswithleukopeniahypophosphatemiaandbonemarrowt1hyperintensity |